Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition

Kenji Takeuchi, Chie Yokouchi, Hirohiko Goto, Ken Umehara, Hideyuki Yamada, Yuji Ishii

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Nonalcoholic fatty liver disease (NAFLD) has increased worldwide in recent years. NAFLD is classified into two types, nonalcoholic fatty liver (NAFL), with few complications, and nonalcoholic steatohepatitis (NASH), which leads to liver cirrhosis or cancer. This study was based on previous reports that N 1 -methylnicotinamide (MNA) can stabilise sirtuin 1 protein, leading to decreased lipid levels in the liver. We hypothesised that fatty liver improvement by MNA would be further enhanced by suppressing its rapid metabolism by aldehyde oxidase in the liver. To test this, hydralazine (HYD), a potent aldehyde oxidase inhibitor, was administered orally to NAFL model rats. Liver triglyceride (TG) levels in the model were nearly unchanged by administration of MNA alone. In contrast, TG levels were marked decreased in NAFL rats treated with a combination of MNA and HYD. In addition, TG levels were decreased even in NAFL rats treated with only HYD. These findings supported our hypothesis that maintaining MNA concentrations in the liver, by suppressing MNA metabolism, would at least partially ameliorate fatty liver.

元の言語英語
ページ(範囲)203-210
ページ数8
ジャーナルBiochemical and Biophysical Research Communications
507
発行部数1-4
DOI
出版物ステータス出版済み - 12 9 2018

Fingerprint

Aldehyde Oxidase
Fatty Liver
Liver
Biological Availability
Rats
Hydralazine
Triglycerides
Sirtuin 1
Metabolism
Liver Neoplasms
N(1)-methylnicotinamide
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis
Lipids

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

これを引用

Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition . / Takeuchi, Kenji; Yokouchi, Chie; Goto, Hirohiko; Umehara, Ken; Yamada, Hideyuki; Ishii, Yuji.

:: Biochemical and Biophysical Research Communications, 巻 507, 番号 1-4, 09.12.2018, p. 203-210.

研究成果: ジャーナルへの寄稿記事

Takeuchi, Kenji ; Yokouchi, Chie ; Goto, Hirohiko ; Umehara, Ken ; Yamada, Hideyuki ; Ishii, Yuji. / Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition :: Biochemical and Biophysical Research Communications. 2018 ; 巻 507, 番号 1-4. pp. 203-210.
@article{0f717cdf59a24b2b895e132a43efb943,
title = "Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition",
abstract = "Nonalcoholic fatty liver disease (NAFLD) has increased worldwide in recent years. NAFLD is classified into two types, nonalcoholic fatty liver (NAFL), with few complications, and nonalcoholic steatohepatitis (NASH), which leads to liver cirrhosis or cancer. This study was based on previous reports that N 1 -methylnicotinamide (MNA) can stabilise sirtuin 1 protein, leading to decreased lipid levels in the liver. We hypothesised that fatty liver improvement by MNA would be further enhanced by suppressing its rapid metabolism by aldehyde oxidase in the liver. To test this, hydralazine (HYD), a potent aldehyde oxidase inhibitor, was administered orally to NAFL model rats. Liver triglyceride (TG) levels in the model were nearly unchanged by administration of MNA alone. In contrast, TG levels were marked decreased in NAFL rats treated with a combination of MNA and HYD. In addition, TG levels were decreased even in NAFL rats treated with only HYD. These findings supported our hypothesis that maintaining MNA concentrations in the liver, by suppressing MNA metabolism, would at least partially ameliorate fatty liver.",
author = "Kenji Takeuchi and Chie Yokouchi and Hirohiko Goto and Ken Umehara and Hideyuki Yamada and Yuji Ishii",
year = "2018",
month = "12",
day = "9",
doi = "10.1016/j.bbrc.2018.11.008",
language = "English",
volume = "507",
pages = "203--210",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1-4",

}

TY - JOUR

T1 - Alleviation of fatty liver in a rat model by enhancing N 1 -methylnicotinamide bioavailability through aldehyde oxidase inhibition

AU - Takeuchi, Kenji

AU - Yokouchi, Chie

AU - Goto, Hirohiko

AU - Umehara, Ken

AU - Yamada, Hideyuki

AU - Ishii, Yuji

PY - 2018/12/9

Y1 - 2018/12/9

N2 - Nonalcoholic fatty liver disease (NAFLD) has increased worldwide in recent years. NAFLD is classified into two types, nonalcoholic fatty liver (NAFL), with few complications, and nonalcoholic steatohepatitis (NASH), which leads to liver cirrhosis or cancer. This study was based on previous reports that N 1 -methylnicotinamide (MNA) can stabilise sirtuin 1 protein, leading to decreased lipid levels in the liver. We hypothesised that fatty liver improvement by MNA would be further enhanced by suppressing its rapid metabolism by aldehyde oxidase in the liver. To test this, hydralazine (HYD), a potent aldehyde oxidase inhibitor, was administered orally to NAFL model rats. Liver triglyceride (TG) levels in the model were nearly unchanged by administration of MNA alone. In contrast, TG levels were marked decreased in NAFL rats treated with a combination of MNA and HYD. In addition, TG levels were decreased even in NAFL rats treated with only HYD. These findings supported our hypothesis that maintaining MNA concentrations in the liver, by suppressing MNA metabolism, would at least partially ameliorate fatty liver.

AB - Nonalcoholic fatty liver disease (NAFLD) has increased worldwide in recent years. NAFLD is classified into two types, nonalcoholic fatty liver (NAFL), with few complications, and nonalcoholic steatohepatitis (NASH), which leads to liver cirrhosis or cancer. This study was based on previous reports that N 1 -methylnicotinamide (MNA) can stabilise sirtuin 1 protein, leading to decreased lipid levels in the liver. We hypothesised that fatty liver improvement by MNA would be further enhanced by suppressing its rapid metabolism by aldehyde oxidase in the liver. To test this, hydralazine (HYD), a potent aldehyde oxidase inhibitor, was administered orally to NAFL model rats. Liver triglyceride (TG) levels in the model were nearly unchanged by administration of MNA alone. In contrast, TG levels were marked decreased in NAFL rats treated with a combination of MNA and HYD. In addition, TG levels were decreased even in NAFL rats treated with only HYD. These findings supported our hypothesis that maintaining MNA concentrations in the liver, by suppressing MNA metabolism, would at least partially ameliorate fatty liver.

UR - http://www.scopus.com/inward/record.url?scp=85057280986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057280986&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2018.11.008

DO - 10.1016/j.bbrc.2018.11.008

M3 - Article

C2 - 30446221

AN - SCOPUS:85057280986

VL - 507

SP - 203

EP - 210

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1-4

ER -